A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer

Phase 1

Terminated

• Conditions: Castration-resistant Prostate Cancer
• Interventions: Biological: DCVac/PCa; Drug: Cyclophosphamide

• Registration Number: NCT03514836
• Lead Sponsor: SOTIO a.s.

Brief Summary

This clinical trial is to evaluate the safety of the combination of DCVAC/PCa with ONCOS-102 in men with castration-resistant advanced metastatic prostate cancer, who have progressed following initial therapy with either hormones (e.g. abiraterone and enzalutamide) or chemotherapy.

Male patients with castration-resistant advanced metastatic prostate cancer, who have progressed following initial therapy with either All patients must have at least one readily accessible soft tissue/nodal tumor lesion (for intra-tumoral application of ONCOS-102 and biopsy.

Detailed Description

Study Description:

* All patients who fulfill all eligibility criteria will undergo a leukapheresis procedure.

* ONCOS-102 administration will start within 3 weeks of leukapheresis at Week 5 (35 days since baseline +/- 2 days), and 3 further doses will be administered on a weekly basis

* Cyclophosphamide A priming bolus dose of CPO (300 mg/m2 intravenously) will be given 1-3 days before the first (Week 5) and the fifth (Week 14) of ONCOS-102 administration.

* DCVAC/PCa therapy will start 6 weeks after leukapheresis at Week 8. DCVAC/PCa will be administered subcutaneously in cycles, always on Day 1 (+/- 3 days) of the corresponding cycle.

Study Timeline

• Study First Submitted: 2018-04-11
• Study First Submitted QC: 2018-05-01
• Study First Posted: 2018-05-02
• Study Start: 2018-05-23
• Status Verified: 2021-01
• Primary Completion: 2021-01-25
• Study Completion: 2021-01-25
• Last Update Submitted: 2021-01-27
• Last Update Posted: 2021-02-01

Recruitment & Eligibility

• Status: TERMINATED
• Sex: Male
• Target Recruitment: 5

Inclusion Criteria

• Histologically or cytologically confirmed adenocarcinoma of the prostate
• Radiographically documented metastatic disease with evidence of disease progression Laboratory parameters per protocol
• Surgically or medically castrate
• Patients who have progressed following:
• a. at least initial therapy (chemotherapy or treatment with a hormonal agent known to impact survival such as abiraterone and enzalutamide); or
• b. one first-line chemotherapy regimen and one additional hormonal agent known to impact survival such as abiraterone and enzalutamide; or
• c. failure of two lines of chemotherapy; or
• d. failure of pre-chemotherapy abiraterone or enzalutamide and subsequent chemotherapy

Read More

Exclusion Criteria

• Patients with neuroendocrine or small cell cancer of the prostate 2. History of other malignant disease (with the exception of the primary prostate cancer and non-melanoma skin tumors) in the past 5 years Pre-defined co-morbidities
• Administration of experimental therapy within the last 4 weeks before start of screening
• Treatment with immunotherapy within the last 3 months before start of screening
• Treatment with radiopharmaceutical drugs within 8 weeks before start of screening
• Receipt of oncolytic virus treatment or vaccination with a live virus within 4 weeks of study start
• History of organ transplantation

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
DCVac and ONCOS-102	DCVac/PCa	ONCOS-102 is given intra-tumor up to 4 times, cyclophosphamide is given prior to the first dose of ONCOS-102 and at the fifth week of treatment DCVac is given sc every 21-28 days for up to 10 doses
DCVac and ONCOS-102	Cyclophosphamide	ONCOS-102 is given intra-tumor up to 4 times, cyclophosphamide is given prior to the first dose of ONCOS-102 and at the fifth week of treatment DCVac is given sc every 21-28 days for up to 10 doses

Primary Outcome Measures

Name	Time	Method
Progression Free Survival	96 months	PFS measured by modifications to the RECIST 1.1. PFS is defined as the time from the first dose of SoC therapy administered to tumor progression or death from any cause.

Secondary Outcome Measures

Name	Time	Method
Time to Progression-PSA	96 months	demonstrated by rising PSA as defined by the Prostate Cancer Workging Group2
Overall Survival	96 months	Defined as the time from Baseline visit to the date of death for any cause
Radiographic Progression- free survival	96 months	composite assessment of progression of bone lesions, soft-tissue lesions or death due to any cause
Safety	96 months	Reports of adverse events, serious adverse events, lab abnormalities utilizing NCI CTCAE v.4.033

Trial Locations

Locations (1)

Fakultní nemocnice v Motole; 🇨🇿 Praha, Czechia